Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semuloparin for Extended VTE Prevention in Hip Fracture Surgery
NCT00709904Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jun 2008
- Primary completion
- Jan 2010
- Modality
- Peptides, Small Molecules
- Countries
- 16
01
Overview
Phase 3, randomised, double-blind trial in venous thromboembolism (VTE) comparing Semuloparin Extension with Placebo Extension (2 arms). Primary endpoint: Percentage of Participants Who Experience Venous Thromboembolism Events (VTE) or Death From Any Cause During the Extension Treatment Period up to 24 days. Started Jun 2008; status: completed.
02
Drugs
semuloparin
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT00709904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00709904.